Session Title: AMD II
Session Date/Time: Friday 18/09/2015 | 14:30-16:00
Paper Time: 15:18
First Author: : C.Petry ARGENTINA
Co Author(s): : A. Ferrero N. Rosso Nano G. Russo N. Rivero Covre M. Vidosevich F. Bilbao
PURPOSE:To describe the baseline characteristics of the 222 neovascular age-related macular degeneration (nAMD) and 91 diabetic macular edema (DME) patients recruited in Argentina, who were among the first 20085 patients recruited into the LUMINOUS study prior to the second interim analyses in March 2013, and compare these with the Global cohort.
LUMINOUS is an ongoing 5-year, prospective, multinational, observational study of the use of ranibizumab in clinical practice across all approved indications.
LUMINOUS will evaluate the long-term safety, effectiveness, treatment patterns, and health-related quality of life of patients treated with ranibizumab 0.5mg (RBZ) in routine clinical practice. Consenting adult patients, treatment naïve or with prior RBZ or other ocular treatment, (with the exception of VEGF inhibitors other than RBZ given within 90 days of study entry), have been recruited.
Compared to the Global cohort, more patients were treatment naïve in the Argentina group for nAMD (50% vs 26%) and for DME (58% vs 27%), and fewer patients had received prior RBZ therapy for nAMD (47% vs 72%) and for DME (31% vs 40%). Median time from diagnosis to first treatment for treatment naïve patients was longer for Argentina in both indications: nAMD (0.35 vs 0.016 years) and DME (0.39 vs 0.003 years); however, Median time from diagnosis to study entry in the prior RBZ group was shorter for the Argentinian cohort in both indications: nAMD (0.86 vs 1.44 years) and DME (0.78 vs 1.59 years). Mean BCVAs were lower in the Argentinian cohort for the treatment naïve (nAMD 33.8 vs 48.8; DME 40.8 vs 55.5) and previous RBZ groups (nAMD 38.2 vs 56.4; DME 41.1 vs 57.8). Baseline comorbidities were lower for Argentinian cohorts for hypertension (nAMD 35% vs 56.7%; DME 36% vs 67.2%), family history of coronary artery disease (nAMD 4.5% vs 14.9%; DME 13.2% vs 14.1%), stroke (nAMD 1.4% vs 5.6%; DME 1.1% vs 6.1%) and myocardial infarction (nAMD 3.2% vs 7.3%; DME 4.4% vs 7.4%).
In both the nAMD and DME Argentinian groups, there were more treatment naïve patients. The median time from diagnosis to first treatment in naïve patients, and the time from diagnosis to study entry in patients previously receiving ranibizumab for both nAMD and DME were longer for Argentina. For both pathologies, Argentinian patients presented with fewer comorbidities at baseline and also lower BCVA than the Global cohort. Follow up of Argentinian cohort will provide valuable data from real world nAMD and DME patients, often under-represented in RCTs